Document:

Exhibit

Exhibit 10.6

LUMINEX CORPORATION
RESTRICTED SHARE UNIT AGREEMENT
(OFFICERS AND EMPLOYEES)

     
THIS RESTRICTED SHARE UNIT AGREEMENT (this “Agreement”) is made and entered into as of __________ (the “Grant Date”), between Luminex Corporation, a Delaware corporation (the “Company”), and _________________________ (the “Grantee”). Capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in the Luminex Corporation 2018 Equity Incentive Plan (the “Plan”). 
     
WHEREAS, the Company has adopted the Plan, which permits the issuance of Restricted Share Units; and 

WHEREAS, pursuant to the Plan, the Committee responsible for administering the Plan has granted an award of Restricted Share Units to the Grantee in his or her capacity as an employee of the Company or one of its Subsidiaries as provided herein. 
     
NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows: 
   
1.    Grant of Restricted Share Unit Award. 
          
1.1    The Company hereby grants to the Grantee an award (the “Award”) of _____ Restricted Share Units (“RSUs”) on the terms and conditions set forth in this Agreement and as otherwise provided in the Plan. 
          
1.2    The Grantee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof. The terms of this Agreement are governed by the terms of the Plan, and in the case of any inconsistency between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall govern. 
          
1.3    The Grantee’s rights with respect to the Award shall remain forfeitable at all times prior to the dates on which the RSUs shall vest in accordance with Section 2 hereof. 
     
2.    Vesting and Payment. 
          
2.1    Except as provided in Section 2.3, the Award shall vest on the following date(s):
    
	
			
	Units
	 
	Vest Date(s)

	 
	 
	 

2.2    The Grantee shall be entitled to payment in respect of each RSU covered by the Award upon the vesting of such RSU. Subject to the provisions of the Plan, such payment shall be made through the issuance to the Grantee, as promptly as practicable following the applicable vesting date (or to the executors or administrators of Grantee’s estate, as promptly as practicable after the Company’s receipt of notification of Grantee’s death, as the case may be), of a stock certificate for a number of Shares equal to the number of such vested RSUs, less any Shares withheld to satisfy withholding obligations in accordance with Section 5 below. 
          
2.3    Except as otherwise determined by the Committee at or after the grant of the Award hereunder, Grantee shall forfeit all unpaid RSUs granted hereunder, and all rights of the Grantee to the Shares payable with respect to such RSUs shall terminate, without further obligation on the part of the Company, unless the Grantee remains in the continuous employment (or other service-providing capacity) of the Company or its Subsidiaries for the entire period beginning on the Grant Date and ending on the vest date applicable to such RSUs as provided in Section 2.1. “Continuous employment” will be deemed to end on the date on which notice of termination is received by the Grantee (or such later date as specified in such notice by the Company) or notice of resignation is given by the Grantee. Notwithstanding the foregoing, the Award shall automatically vest as to all RSUs awarded hereunder (as to which such RSUs have not previously vested) upon the occurrence of termination of the Grantee’s employment from the Company, a Subsidiary or Affiliate which results from Grantee’s death or Disability (to be determined in the sole discretion of the Committee). 

     
3.    Dividend Equivalents; No Voting Rights. RSUs covered by this Award shall be credited with dividend equivalents at the time of any payment of dividends to shareholders on Shares as follows: the amount of any cash, or the Fair Market Value of any Shares, payable as a dividend with respect to a corresponding number of Shares shall be converted into additional RSUs based on the Fair Market Value of a Share at the time such dividends are paid, provided that such RSUs shall be subject to the same forfeiture restrictions and restrictions on transferability as apply to the RSUs with respect to which they relate. Any dividend equivalent rights shall be paid in accordance with the Company’s payment practices as of the date on which such dividend would have been payable in respect of outstanding Shares.  The Grantee shall not be entitled to voting rights with respect to RSUs covered by this Award.  No shares are actually awarded to Grantee on the date of grant and Grantee shall have no rights of a stockholder with respect to RSUs until the restrictions set forth herein have lapsed.  
     
4.    No Right to Continued Service. Nothing in this Agreement or the Plan shall be interpreted or construed to confer upon the Grantee any right to continue service as an employee of the Company, any Subsidiary or Affiliate, and the Company or its Subsidiaries or Affiliates may at any time dismiss Grantee from employment, free from any liability or any claim under the Plan but subject to the terms of the Grantee’s employment agreement, if any. 
     
5.    Withholding of Taxes. Upon the vesting and payment of the RSUs granted hereunder, the Company shall be entitled to satisfy any required tax withholding obligation (at such rate determined by the Committee in conformity with applicable law and not to exceed the statutory maximum rate) imposed by any applicable taxing authority by (a) withholding from payment to Grantee upon vesting of the RSUs such number of Shares having a Fair Market Value equal to any such withholding obligation, (b) requiring Grantee, as a condition to receiving Shares otherwise payable pursuant to Section 2.3 hereof, to remit a cash payment to the Company sufficient to allow the Company to satisfy such withholding obligations, or (c) any other method determined by the Committee in its sole discretion. 
 
 6.    Modification of Agreement. Subject to the restrictions contained in the Plan, the Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate, the Award, prospectively or retroactively; provided that any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would adversely affect the rights of the Grantee or any holder or beneficiary of the Award shall not to that extent be effective without the consent of the Grantee, holder or beneficiary affected. 
     
7.    Severability. If any provision of this Agreement is, or becomes, or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Person or the Award, or would disqualify the Plan or Award under any laws deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the Plan and Award shall remain in full force and effect. 
     
8.    Governing Law. The validity, interpretation, construction, effect and performance of this Agreement shall be governed by the laws of the State of Delaware without giving effect to the conflicts of law principles thereof, except to the extent that such laws are preempted by Federal law. 
     
9.    Successors in Interest. This Agreement shall inure to the benefit of and be binding upon any successor to the Company. This Agreement shall inure to the benefit of the Grantee’s legal representatives. All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors, administrators and successors. 
     
10.    Resolution of Disputes. Any dispute or disagreement which may arise under, or as a result of, or in any way related to, the interpretation, construction or application of this Agreement shall be determined by the Committee. Any determination made hereunder shall be final, binding and conclusive on the Grantee and the Company for all purposes.   The Grantee may contest a decision or action by the Committee with respect to such Grantee only on the grounds that such decision or action was arbitrary or capricious or was unlawful, and any review of such decision or action shall be limited to determining whether the Committee’s decision or action was arbitrary or capricious or unlawful.
     
11.    Notices. All notices required to be given under this Award shall be deemed to be received if delivered or mailed as provided for herein, to the parties at the following addresses, or to such other address as either party may provide in writing from time to time. 

To the Company:        Luminex Corporation
12212 Technology Blvd.
Austin, TX  78727
Attn: Corporate Secretary and Chief Financial Officer

To the Grantee:        The address then maintained with respect to the Grantee in the Company's records.

IN WITNESS WHEREOF, the parties have caused this Restricted Share Unit Agreement to be duly executed effective as of the day and year first above written. 

LUMINEX CORPORATION

By:  /s/ Harriss T. Currie

Harriss T. Currie
Senior Vice President, Finance
Chief Financial Officer

            
GRANTEE:

__________________________________________
Please Print

GRANTEE:

__________________________________________
SignatureExhibit 10.1

 

 

SECOND AMENDMENT TO
LICENSE

AGREEMENT

 

This Second Amendment to
the License Agreement (the “Second Amendment”), effective on the last signature date below (“Amendment Effective
Date”), is by and between NORTH CAROLINA STATE UNIVERSITY (“NCSU”) and 22nd CENTURY LIMITED, LLC
(“Licensee”). Hereinafter NCSU and the Licensee are referred to collectively as the “Parties.”

 

WHEREAS, the Parties have
executed a License Agreement (the “License Agreement”) with an effective date of December 8th, 2015, for certain Patent
Rights and Plant Material owned by NCSU (License Agreement #160829MA);

 

WHEREAS, the Parties have
executed a First Amendment to the License Agreement (the “First Amendment”) with an effective date of February 14th,
2018, amending and clarifying the License Agreement; and

 

WHEREAS, NCSU and Licensee
entered into a Sponsored Project Agreement on February 10, 2014 (“NCSU Radar number 2014-1405”) (the “Sponsor
Agreement”); and

 

WHEREAS, the Sponsor Agreement
was modified and extended pursuant to a Modification No. 1 executed as of April 13, 2016 (“Modification 1”), Modification
No. 2 executed as of February 7, 2017 (“Modification 2”), Modification No. 3 effective as of April 30, 2017 (“Modification
3”), and Modification No. 4 effective as of April 30, 2018 (“Modification 4”).

 

WHEREAS, since as early as January
1, 2008 and up to the present, NCSU has been conducting: (i) research under a grant from The Tobacco Education and Research Council
(“TERC”) directed to “development of non-GMO tobacco cultivars with reduced alkaloid content” (Project
Number 2007-12) and research initially sponsored by TERC entitled “TN90 222, K326 222, NC775 222, and NC645 222 tobacco inbred
lines possessing deleterious mutations in the three major bbl genes involved in nicotine biosynthesis” (NCSU File No. 18260),
which research has resulted in the development of certain tangible biological materials; and (ii) research under a proposal entitled
“Development of High Quality, Non-GM Tobacco Cultivars with Reduced Alkaloid Content,” which research was funded through
a charitable contribution in support of the so-called Tobacco Program in CALS at NCSU under RJRTC Contract No. 10-33700-004 (“RJRTC”)
and has resulted in the development of certain tangible biological materials possessing deleterious mutations in the three major
bbl genes involved in nicotine biosynthesis, (all of the forgoing research in (i) and (ii) above hereinafter collectively referred
to as the “NCSU Research”);

 

WHEREAS,
TERC and RJRTC do not have any commercial rights in the results of the NCSU Research, and no other third party has any rights of
any nature in the results of the NCSU Research;

 

WHEREAS,
the Sponsor Agreement is being further modified and extended by a Modification No. 5 being entered into by NCSU and Licensee contemporaneously
with this Second Amendment (“Modification 5”), pursuant to which NCSU will further the NCSU Research as part of and
under the Sponsor Agreement;

 

WHEREAS, NCSU and Licensee
have confirmed and acknowledge that any and all past, present and/or future Intellectual Property
(as defined in the Sponsor Agreement), including without limitation Tangible Biological Materials, developed by NCSU pursuant to
the Sponsor Agreement, as previously or hereafter modified, is included in the Patent Rights and Plant Material under the License
Agreement;

 

     
 

     

    

 

WHEREAS, NCSU and Licensee
desire to include any and all results, including without limitation any and all tangible biological
materials, of the NCSU Research in the Patent Rights, Licensed Know-How and Plant Material under the License Agreement;
and

 

WHEREAS, NCSU and Licensee
desire make certain further clarifications and additions to the License Agreement in view of the research by NCSU being sponsored
by Licensee pursuant to the Sponsor Agreement as modified.

 

NOW, THEREFORE, in consideration
of the mutual premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto intending to be legally bound do hereby agree to amend and clarify the License Agreement,
in accordance with Article 24 of the License Agreement, as follows:

 

1. The term “Sponsor Agreement”
in Recital A. of the License Agreement and hereafter shall include Modification 1, Modification 2, Modification 3, Modification
4, Modification 5, and any further modifications of or amendments to the Sponsor Agreement.

 

2. Pursuant to the First
Amendment, the license grant of Article 2.01 of the License Agreement includes an exclusive, worldwide right and license to use
and commercialize Licensed Know-How. “Licensed Know-How” is hereby amended to mean any and all information, including
but not limited to test results, data, research methodologies and transformation processes, (i) related to any Plant Materials
arising or resulting from the research by NCSU being sponsored by Licensee pursuant to the Sponsor Agreement or developed or created
under the Sponsor Agreement, (ii) developed or created with the use of any confidential information, equipment, materials of Licensee
pursuant to the Sponsor Agreement, or (iii) related to any Plant Materials that arose or resulted from the NCSU Research or that
were developed or created in connection with the NCSU Research. The foregoing exclusive license is subject to and does not in any
way limit NCSU’s right to publish as provided under Article 9 of the Sponsor Agreement.

 

3. Article 1.09 of the License
Agreement defining “Plant Materials” is deleted in its entirety and replaced with the following:

 

1.09“Plant
Material” means (i) the materials listed in Appendix B and any materials derived or propagated from the materials listed
in Appendix B; (ii) any and all materials developed in the past, present and/or future performance of the research under the Sponsor
Agreement, as previously, now or hereafter modified, and any materials derived or propagated from such materials; (iii) any and
all materials developed in the past, present or future performance of the NCSU Research and any materials derived or propagated
from such materials; and (iv) any and all materials developed in the past, present or future by or under the direction, supervision
or auspices of Dr. Ralph Dewey and/or Dr. Ramsey Lewis that use or contain one or more mutant BBL genes (regardless of when, how,
and where within a given gene the mutation was made) and any materials derived or propagated from such materials.

 

4. Article 1.10 of the License
Agreement defining “Patent Rights” is deleted in its entirety and replaced with the following:

 

     
 

     

    

 

1.10“Patent
Rights” means (a) the patents and patent applications listed in Appendix A; (b) any and all patent applications now or hereafter
filed with respect to the Sponsored IP; (c) any and all patent applications now or hereafter filed with respect to the NCSU Research;
(d) any and all patent applications now or hereafter filed for an invention that uses or comprises one or more mutant BBL genes
(regardless of when, how, and where within a given gene the mutation was made) for which Dr. Ralph Dewey and/or Dr. Ramsey Lewis
is an inventor; (e) any and all patent applications now or hereafter filed covering any Plant Material; (f) any and all applications
claiming the benefit of the filing date or claiming priority from any of the foregoing patent applications, including without limitation
all divisional applications, continuation applications, continuation-in-part applications, reissue applications, reexaminations
and extensions, and all foreign corresponding or counterpart international, regional and national applications; and (g) any and
all patents issuing or reissuing from any of the foregoing patent applications. Notwithstanding the foregoing, Patent Rights does
not include those patents and/or patent applications that, during the term of this License Agreement, cease to be Patent Rights
pursuant to Article 8.01 or 8.03.

 

5. The following is added
at the end of Article 2.05 of the License Agreement:

 

Notwithstanding the foregoing, NCSU shall not
be required to deliver Plant Materials that include a genetic trait defined by loss-of-function mutations in the nicotine demethylase
genes CYP82E4, CYP82E5 and CYP82E10 (the “SRC Trait”), which SRC Trait is also known as ZyvertTM and has
been exclusively licensed by NCSU to a third party (“Third-Party Company”), until Licensee confirms to NCSU in writing
that 22nd Century has procured a license to the SRC Trait from the Third-Party Company. The Plant Materials that include
the SRC Trait (the “SRC Materials”) in NCSU’s possession specifically include TN90 SRC 222 and K326 SRC 222 lines
and intermediates thereof, which SRC Materials are in the sole possession of Dr. Ramsey Lewis and Dr. Ralph Dewey and are subject
to the restrictions on Plant Materials set forth in this License Agreement.

 

6. “APPENDIX B –
PLANT MATERIALS” of the License Agreement is deleted in its entirety and replaced with the following:

 

APPENDIX B—PLANT MATERIALS

 

(Plant Materials includes plants and seeds of the lines listed
below and any materials derived therefrom).

 

For avoidance of any doubt, it is understood that the
ability of NCSU to provide any Plant Material to the Licensee depends on whether such Plant Material(s) has been developed/created
and is available at time of such request.

  

		1.	Specific tobacco plants homozygous for EMS-induced knockout mutations in the BBLa, BBLb and BBLc loci
that ADDITIONALLY possess custom-designed nuclease-mediated mutations at BBLe and/or BBLd-1 and/or
BBLd-2. These Plant Materials are listed below:

 

		a.	In the flue-cured background K326 (ems=mutation induced by the chemical mutagen ethyl methane sulfonate; tm= targeted mutation
induced by a designer nuclease; all loci listed are assumed to be homozygous; lower case loci are mutant, upper case loci are wild
type):

		i.	K326 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/BBLd-2/BBLe)

		ii.	K326 (bbla-ems/bblb-ems/bblc-ems/BBLd-1/bbld-2-tm/BBLe)

 

     
 

     

    

 

		iii.	K326 (bbla-ems/bblb-ems/bblc-ems/BBLd-1/BBLd-2/bble-tm)

		iv.	K326 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/bbld-2-tm/BBLe)

		v.	K326 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/BBLd-2/bble-tm)

		vi.	K326 (bbla-ems/bblb-ems/bblc-ems/BBLd-1/bbld-2-tm/bble-tm)

		vii.	K326 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/bbld-2-tm/bble-tm)

		b.	In the burley background TN90 (ems=mutation induced by the chemical mutagen ethyl methane sulfonate; tm= targeted mutation
induced by a designer nuclease; all loci listed are assumed to be homozygous; lower case loci are mutant, upper case loci are wild
type):

		i.	TN90 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/BBLd-2/BBLe)

		ii.	TN90 (bbla-ems/bblb-ems/bblc-ems/BBLd-1/bbld-2-tm/BBLe)

		iii.	TN90 (bbla-ems/bblb-ems/bblc-ems/BBLd-1/BBLd-2/bble-tm)

		iv.	TN90 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/bbld-2-tm/BBLe-tm)

		v.	TN90 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/BBLd-2/bble-tm)

		vi.	TN90 (bbla-ems/bblb-ems/bblc-ems/BBLd-1/bbld-2-tm/bble-tm)

		vii.	TN90 (bbla-ems/bblb-ems/bblc-ems/bbld-1-tm/bbld-2-tm/bble-tm)

		2.	Specific tobacco plants that exclude EMS induced knockout mutations in BBLa, BBLb and BBLc loci [mentioned
above in APPENDIX B Sections 1(a) and 2(b)]. These Plant Materials are listed below:

		a.	K326 background: tobacco plants possessing any combination of custom-designed nuclease-induced mutations in BBLa, BBLb
and BBLc (generated by construct BBL 15-16x.20, and/or other comparable Precision Biosciences constructs), either alone
or in combination with any of the custom-designed nuclease induced mutations and mutant combinations in BBLe, BBLd-1
and BBLd-2 defined above in APPENDIX B Sections 1(a).

		b.	TN90 background: tobacco plants possessing any combination of custom-designed nuclease induced mutations in BBLa, BBLb
and BBLc (generated by construct BBL 15-16x.20, or comparable Precision Bioscience construct), either alone or in combination
with any of the custom-designed nuclease induced mutations and mutant combinations in BBLe, BBLd-1 and BBLd-2
defined above in section APPENDIX B Sections 1(b).

 

		3.	All plants included above in APPENDIX B, Section 1, and APPENDIX B, Section 2, which additionally contain one or both of the
naturally occurring low alkaloid mutant loci referred to as nic1 and nic2, as well as induced mutations in the various
genes of the alkaloid biosynthetic pathway encoding the enzymes ornithine decarboxylase (ODC), putrescine methyltransferase (PMT),
methylputrescine oxidase (MPO), quinolate phosphoribosyltransferase (QPT) or the isoflavone reductase-like protein referred to
as A622. The materials can possess any combination of the aforementioned loci.

 

		4.	All plants developed from the NCSU Research, including without limitation the Plant Materials listed below:

 

		a.	K326 222 – a BC7F3 nearly isogenic version of flue-cured tobacco cultivar K326 carrying the three
major bbl mutations in homozygous condition.

		b.	TN90 222– a BC7F3 nearly isogenic version of burley tobacco cultivar TN90 carrying the three major
bbl mutations in homozygous condition.

		c.	NC645 222 (segregating) - NC645 is the pollen parent of burley tobacco cultivar 'NC7' which is agronomically superior to TN90. 
We have a BC7F2 nearly-isogenic family that will segregate for the three major bbl mutations.

 

     
 

     

    

 

		d.	NC775 222 (segregating) - NC775 is the female parent of burley tobacco cultivar 'NC7' which is agronomically superior
to TN90.  We have a BC7F2 nearly-isogenic family that will segregate for the three major bbl mutations.

		e.	Flue-cured tobacco lines of primarily K326 descent that are homozygous for the three major bbl mutations, and also homozygous
for the recessive nic1 allele.

		f.	Flue-cured tobacco lines of primarily K326 descent that are homozygous for the three major bbl mutations, and also homozygous
for the recessive nic2 allele.

		g.	Flue-cured tobacco lines of primarily K326 descent that are homozygous for the three major bbl mutations, and also homozygous
for the recessive nic1 and nic2 alleles.

		h.	Burley tobacco lines of primarily TN90 descent that are homozygous for the three major bbl mutations, and also homozygous for
the recessive nic1 allele.

		i.	Burley tobacco lines of primarily TN90 descent that are homozygous for the three major bbl mutations, and also homozygous for
the recessive nic2 allele.

		j.	Burley tobacco lines of primarily TN90 descent that are homozygous for the three major bbl mutations, and also homozygous for
the recessive nic1 and nic2 alleles.

		5.	All plants included above in APPENDIX B, Section 1, and APPENDIX B, Section 2, in which mutations in the BBLd-1, BBLd-2,
or BBLe genes are in either a heterozygous or homozygous state.

		6.	All other “Tangible Biological Materials” as defined in the Sponsor Agreement.

 

Because of the exceedingly
large number of BBL mutant combinations that are possible under here, NCSU will not generate every possible BBL mutant combination
within K326 and/or TN90. NCSU will consult with 22nd Century in deciding which specific mutant combinations are desirable, and
within reason will attempt to generate/develop them. As mentioned above, and for clarity and avoidance of any doubt, it is understood
that the ability of NCSU to provide any Plant Material to 22nd Century depends on whether such Plant Material(s) has been developed/created
and is available at time of such request.

 

7. “APPENDIX C –
MILESTONE FEES” of the License Agreement is deleted in its entirety and replaced with the following:

 

Appendix
c—MILESTONE FEES

 

		1.	A one-time, non-refundable, non-creditable payment of US Five Hundred Thousand Dollars (US$500,000)
payable within five (5) business days after execution of this Second Amendment.

 

		2.	A one-time, non-refundable, non-creditable payment
of US Four Hundred Thousand Dollars (US$400,000) payable on or before the first calendar year anniversary of the execution of this
Second Amendment.

 

		3.	A one-time, non-refundable, non-creditable payment of US Three Hundred Thousand Dollars (US$300,000)
payable on or before the second calendar year anniversary of the execution of this Second Amendment.

 

8. All capitalized terms
used in this Second Amendment that are not otherwise defined in this Second Amendment have the meanings assigned to them in the
License Agreement or the First Amendment.

     
 

     

    

9. Except as expressly amended
herein, all terms and conditions of the License Agreement and First Amendment shall remain in full force and effect and apply to
this Second Amendment as though incorporated herein.

10. This Second Amendment
may not be modified except by written agreement executed by the Parties.

11. The Parties to this Second
Amendment agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which
the original signature may have been used. The Parties further waive any right to challenge the admissibility or authenticity of
this document in a court of law based solely on the absence of an original signature.

IN WITNESS WHEREOF, the Parties have caused this Second
Amendment to be executed by their respective authorized representatives.

  

	NORTH CAROLINA STATE UNIVERSITY	 	22nd CENTURY LIMITED, LLC
	 	 	 
	 	 	 	 	 
	By:	 	 	  By:	 
	 	Kultaran Chohan, Ph.D., LLM., CLP 	 	 	Henry Sicignano III
	 	Director of Licensing 	 	 	President and Manager
	 	Office of Technology Commercialization	 	 	 
	 	and New Venture 	 	 	 
	 	 	 	 	 
	Date:	 	 	Date: 	 

 

 

 

Acknowledged and Accepted by:

 

 

	Dr. Ramsey Lewis	Date
	 	 
	 	 
	 	 
	Dr. Ralph Dewey	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]